BriaCell Clinical Update Shows Progress With Breast Cancer Program
BriaCell Therapeutics Corp. continues to enroll patients in its Phase 1/2a clinical trial of BriaVax for the treatment of advanced breast cancer.
Iomab-B Makes Actinium Pharma A Rare And Exciting Investment Opportunity
BMT is one of the fastest growing hospital procedures according to AHRQ; US Dept. of HHS. Iomab-B offers a better solution - cheaper, faster, safer, and more effective - than the current standard of care.
HedgePath Granted Type C Meeting With FDA
edgePath Pharmaceuticals, Inc. (HPPI) announced the company has been granted a Type C meeting with the U.S. FDA to discuss the interim results from the company's Phase 2b clinical study of SUBA-Cap.
With Cash In Hand, Focus For MabVax Turns To The Clinical Program
This morning, MabVax Therapeutics closed a public offering of $4.1 million in cash. The company offered 1.343 million shares.
Matinas Well Positioned For June Data Read Outs
Matinas BioPharma Holdings, Inc. reported financial results for the first quarter ending March 31, 2017. The company also provided an update on anti-infective drug candidates, MAT2203 and MAT2501.
Continued Progress, Promise With Oryzon's Pipeline
Oryzon is focused on developing epigenetic-based therapies and personalized drugs from its proprietary platform technology. Over the past several months, management has made significant progress moving the pipeline forward.


Latest Comments
Vitality Biopharma Taking Cannabinoid Research To The Next Level
6 years ago

I can't control what others do. It certainly isn't me making random phone calls to people.

In this article: VBIO
Why After A Massive Run, CoLucid Shares Still Look Attractive
6 years ago

What does everyone think of this idea?

In this article: CLCD
1 to 3 of 3 comments


ADMS Adamas Pharmaceuticals, Inc.
AKAO Achaogen, Inc.
AUPH Aurina Pharmaceuticals
BLCM Bellicum Pharmaceuticals Inc
CLSD Clearside BioMedical, Inc.
DEPO Depomed Inc.
GLYC GlycoMimetics Inc
KALV KalVista Pharmaceuticals
LPTX Leap Therapeutics Inc.
NEOS Neos Therapeutics, Inc.
ONCE Spark Therapeutics
PIRS Pieris Pharmaceuticals, Inc.
RDHL RedHill Biopharma Ltd.
SELB Selecta Biosciences Inc.
TGTX TG Therapeutics, Inc.
ZGNX Zogenix Inc.
Load More



Latest Posts
MabVax Teams Up With Memorial Sloan Kettering To Develop CAR T Products
MabVax Therapeutics (Nasdaq: MBVX) announced it has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center (MSK) for the development of novel Chimeric Antigen Receptor (CAR).
Want Fully Independent Biopharma Stock Research?
I am producing independent equity research on small-cap biotech and pharma names. The monthly price is only $50. Please check it out! Jason

Work Experience

Owner & Managing Director
BioNap Consulting, Inc.
July 2015 - Present (8 years)

BioNap Consulting, Inc. is an investor intelligence and strategic advisory firm dedicated to servicing companies in the pharmaceutical, biotechnology, and medical device sector. Our strengths include a deep and profound knowledge of the healthcare industry and our ability to effectively communicate, often at times complicated scientific or financial metrics, to both institutional and individual investors. We have a large following on social media and are well-respected by our peers.

Managing Director & Senior Biotechnology Analyst
Zacks Investment Research
April 2003 - July 2015 (12 years 6 months)

Director of Zacks Small-Cap Institutional Equity Research divison and Senior Biotechnology Analyst

Vice President, Sr. Equity Analyst
Eastover Capital Management
April 1999 - December 2002 (3 years 9 months)
Laboratory Technician
TechLab, Inc.
May 1996 - August 1998 (2 years 4 months)


Wake Forest University
1998 / 2000
Virginia Polytechnic Institute and State University
1992 / 1996
Biochemistry & Molecular Biology
Voorhees High School
1988 / 1992